TriangleCisplatin (NCT06331468)
Cisplatin trial for Uterine Cervix Cancer (NCT06331468). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for women aged eighteen to 120 with untreated cervical squamous, adenosquamous, or adenocarcinoma: selected bulky stages IB3–IIIC1 stage IVA, or stage IVB with limited metastases not needing urgent systemic therapy.
The idea: eight larger external-radiation treatments over two weeks accompany two weekly cisplatin infusions. Four internal-radiation treatments follow. Researchers test response and safety. Radiation is planned within about thirty days. Follow-up tracks progression and survival for two years.
This phase 2 study plans 20 patients. Denise Fabian leads at Kentucky's Markey Cancer Center in Lexington, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.